Mission Statement, Vision, & Core Values (2026) of Bloomage BioTechnology Corporation Limited.

Founded in 2000, Bloomage BioTechnology Corporation Limited (ticker 688363.SS) has grown into the world's largest producer of hyaluronic acid, operating across more than 70 countries with subsidiaries in the United States, France, Japan and South Korea, and is building an integrated biotechnology value chain that spans raw material production to functional skincare and foods; guided by a mission of "Creative technology for vibrant life," the company invested about 10% of revenue in R&D in 2022, pursues a vision of creating a "trillion‑dollar‑level" life and health industry forest through technological, product and brand strength, and anchors its strategy in core values of integrity, innovation, collaboration, sustainability and customer orientation while embedding green, low‑carbon practices into manufacturing and corporate culture-explore how these pillars translate into tangible market positioning, global reach and industry standards.

Bloomage BioTechnology Corporation Limited (688363.SS) - Intro

• Mission: Advance life and health through science-driven bioproducts and industrial integration, delivering high-quality hyaluronic acid and derived solutions to global healthcare and consumer markets.
• Vision: To cultivate a "forest" of a trillion-yuan (RMB) level life and health industry by leveraging biotechnology, scaling production, and integrating upstream-to-consumer capabilities.
• Strategic pillars: vertical integration, technology leadership in HA production, international expansion, product diversification (medical, aesthetic, nutritional), and digital/quality platformization.

• Science & Innovation: Continuous R&D investment to secure technological leadership in HA fermentation, purification, and application engineering.
• Quality & Safety: End-to-end GMP and regulatory compliance across raw material, intermediate and finished product lines.
• Customer-Centricity: Tailored solutions for pharmaceutical, medical aesthetic, cosmetic and functional food clients globally.
• Sustainable Growth: Resource-efficient fermentation, waste-minimization practices, and long-term ecosystem value creation.
• Global Collaboration: Partnerships, M&A and local presence to accelerate market penetration in key regions (US, EU, Japan, Korea).

• Largest global producer of hyaluronic acid by capacity; vertically integrated fermentation-to-formulation model reduces input cost and improves margin control.
• Advanced proprietary fermentation strains and downstream purification technologies yield high-purity HA across molecular weight ranges for differentiated applications.
• Extensive product matrix: HA raw materials (bulk), intermediates (cross-linked HA), medical devices (injectables), cosmeceuticals, and nutraceuticals.

• Technology-First Growth: Prioritize R&D, scale-up platforms and IP protection to maintain leadership in HA and expand into adjacent biomolecules.
• Industrial Ecosystem: Build an integrated "forest" of life & health enterprises - combining upstream fermentation, midstream processing, and downstream consumer brands - targeting trillion-yuan ecosystem value over the long term.
• Profitability with Purpose: Drive margin expansion through product mix improvement (higher-value medical and specialty HA), operational efficiency, and international brand elevation.

• Publicly listed governance framework on SSE (688363.SS) with established disclosure, audit and board oversight practices.
• GMP, ISO and regulatory alignment for medical, cosmetic and food applications to mitigate product and market-access risks.
• Geographic diversification to reduce single-market exposure and sustain export-driven growth.

Bloomage BioTechnology Corporation Limited (688363.SS) - Overview

• Mission: 'Creative technology for vibrant life' - improve life quality and prolong life length through biomaterials innovation.
• Strategic ambition: Build products that make Chinese people confident and proud; become a globally respected Chinese enterprise.
• Innovation drivers: Heavy R&D investment, integrated biomaterials value chain, and product-to-brand capability.
• Sustainability: Integrate green, low-carbon, and environmental protection across production, management, culture, and public welfare.

Core Strategic Pillars

• End-to-end biomaterials value chain - from raw material production through manufacturing to brand building and market channels, pursuing industry-chain transformation and vertical integration.
• R&D-centric growth - sustained investment in research and technology to maintain leadership in hyaluronic acid and related biomaterial technologies.
• Customer and market orientation - product portfolios and branding designed to increase consumer confidence and global recognition.
• Environmental and social governance - embedding green manufacturing practices and public welfare initiatives into corporate operations.

Core Values and Cultural Orientation

• Innovation: Continual investment in R&D and technology platforms to deliver differentiated biomaterial solutions.
• Customer Focus: Products and brands oriented to enhance user confidence and satisfaction.
• Sustainability: Operational decisions aligned with low-carbon, environmentally protective practices and social responsibility.
• Collaboration: Partnerships across upstream raw materials, downstream brands, research institutions, and global channels to scale impact.

Bloomage BioTechnology Corporation Limited (688363.SS) - Mission Statement

• Core mission: transform scientific R&D into scalable products that deliver measurable human health and environmental benefits.
• Industrial ambition: set standards as a leader in the industrial chain for bio-based materials and biologics.
• Supply-chain role: act as a hub to integrate upstream raw materials and downstream manufacturers, reducing fragmentation and improving resilience.
• Value-chain focus: optimize allocation of resources to maximize product value, accessibility and long-term sustainability.

• R&D-driven growth: sustained investment in discovery, process engineering and clinical/industrial validation to maintain technological leadership.
• Product portfolio deepening: build product power across hyaluronic acid (HA), advanced biomaterials, cosmeceuticals and bioactive ingredients.
• Brand elevation: convert technical leadership into trusted global brands that command premium positioning and long-term customer loyalty.
• Scale & resilience: expand capacity and diversified supply sources to withstand geopolitical and market shocks.

• Build standards: lead industry standard-setting for quality, safety and sustainability in HA and biomaterials.
• Integrate chains: invest in upstream feedstock security, midstream production scale and downstream formulation & branding.
• Scale responsibly: prioritize low-carbon, resource-efficient manufacturing and circularity where feasible.
• Create a 'forest' of value: pursue portfolio and ecosystem growth aiming toward a trillion-dollar-level life & health industry through cumulative industrialization and brand ecosystems.

• R&D pipeline velocity - shorten lab-to-market timelines while maintaining regulatory rigor.
• Product mix optimization - expand high-margin, differentiated formulations and medical-grade applications.
• Globalization - deepen presence in EU, North America, and emerging markets through partnerships and local channels.
• Supply-chain diversification - secure raw materials and strategic inventory to reduce single-point risks.

Bloomage BioTechnology Corporation Limited (688363.SS): Vision Statement

• Integrity: Upholding transparency, regulatory compliance, and accountability across supply chains and clinical/quality processes.
• Innovation: Prioritizing breakthrough research in hyaluronic acid, biomaterials, and biopharmaceuticals through sustained R&D investment.
• Collaboration: Building strategic alliances with universities, research institutes, and industry partners to accelerate translation of science to market.
• Sustainability: Committing to resource efficiency, lower emissions, and responsible sourcing across manufacturing and logistics.
• Customer orientation: Designing products and services informed by customer feedback, quality metrics, and lifecycle support.

• R&D intensity: Maintaining double‑digit focus on innovation via multi-year pipelines and translational programs.
• Global market expansion: Scaling export channels and regulatory approvals to grow international sales share.
• Quality & compliance: Continuous improvement in GMP, ISO, and clinical compliance to protect patient safety and brand trust.
• Environmental targets: Implementing energy efficiency and waste reduction projects across production sites.

• Expanded R&D centers and pilot plants to shorten time-to-market for new biomaterial formulations and bioactive products.
• Industry-academia consortia and sponsored research chairs to co-develop advanced delivery systems and regenerative therapies.
• Sustainability roadmap: energy-efficient manufacturing upgrades, circular waste management pilots, and supplier environmental audits.
• Customer excellence framework: integrated feedback loops, post-market surveillance, and technical service teams to boost satisfaction and retention.